- Exchange: NASDAQ GM
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Medical-Drugs
Regulus Therapeutics Inc
+ Add to WatchlistRGLS:US
7.1000 USD 0.1400 1.93%As of 20:10:00 ET on 05/17/2013.
Snapshot for Regulus Therapeutics Inc (RGLS)
| Open: | 7.2500 | Day's Range: | 7.0300 - 7.2500 | Volume: | 86,450 |
|---|---|---|---|---|---|
| Previous Close: | 7.1000 | 52wk Range: | 4.0000 - 7.8900 | 1-Yr Rtn: | - |
Key Statistics for RGLS
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (USD) (ttm) | - |
| Est. EPS (USD) (12/2013) | -0.5700 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 255.65 |
| Shares Outstanding (M) | 36.01 |
| 30 Day Average Volume | 55,357 |
| Price/Book (mrq) | 4.0972 |
| Price/Sale (ttm) | - |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/14/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for RGLS
Company Profile & Key Executives for RGLS
Regulus Therapeutics Inc. operates within the biopharmaceutical industry. The Company's products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulas's research consists of scientists from across the world.
| Kleanthis G XanthopoulosPresident/CEO | Garry E MenzelExec VP:Finance/COO |
| Neil W GibsonChief Scientific Officer | Amy ConradDirector:Investor Relations |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
RGLS News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page